ImmunoPrecise, Mila partner on antibody therapeutics

By The Science Advisory Board staff writers

November 3, 2020 -- ImmunoPrecise Antibodies and artificial intelligence (AI) research institute Mila have formed a partnership to collaborate on research and talent development initiatives for antibody-based therapeutics.

Specifically, the partnership will apply AI to unexplored datasets generated by ImmunoPrecise's therapeutic antibody discovery platforms to help the design of new therapeutics against life-threatening diseases, according to the companies.

ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.
ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine
ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.
ImmunoPrecise subsidiary expands B cell Select platform
IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's...
ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...

Copyright © 2020 scienceboard.net


Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter